chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 59.0
Sex: U
Vaccine: COVID19
Symptoms: Osteoarthritis
Clinical narrative: osteoarthritis is going crazy; This spontaneous case was reported by a consumer and describes the occurrence of OSTEOARTHRITIS (osteoarthritis is going crazy) in a 59-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination.     Concurrent medical conditions included Osteoarthritis.   In May 2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced OSTEOARTHRITIS (osteoarthritis is going crazy). At the time of the report, OSTEOARTHRITIS (osteoarthritis is going crazy) outcome was unknown.            It was reported that the second dose was taken in the end of May. No concomitant medication was reported. The treatment information was unknown.   This case was linked to MOD21-126461, MOD21-126467, MOD21-126468 (E2B Linked Report).   Most recent FOLLOW-UP information incorporated above includes: On 04-Aug-2021: Follow up received and contains no new information.; Sender's Comments:  MOD21-126461: MOD21-126467: MOD21-126468:
Age: 20.0
Sex: F
Vaccine: COVID19
Symptoms: Illness, Impaired work ability, Product dose omission issue
Clinical narrative: Sick for a week after the first dose; Unable to work; Vaccinated with the first dose of the Moderna COVID19 vaccine on 14MAY2021 and yet to receive the second dose; This spontaneous case was reported by a consumer and describes the occurrence of ILLNESS (Sick for a week after the first dose), IMPAIRED WORK ABILITY (Unable to work) and PRODUCT DOSE OMISSION ISSUE (Vaccinated with the first dose of the Moderna COVID19 vaccine on 14MAY2021 and yet to receive the second dose) in a 20-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 003C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 14-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced ILLNESS (Sick for a week after the first dose), IMPAIRED WORK ABILITY (Unable to work) and PRODUCT DOSE OMISSION ISSUE (Vaccinated with the first dose of the Moderna COVID19 vaccine on 14MAY2021 and yet to receive the second dose). At the time of the report, ILLNESS (Sick for a week after the first dose) and IMPAIRED WORK ABILITY (Unable to work) outcome was unknown and PRODUCT DOSE OMISSION ISSUE (Vaccinated with the first dose of the Moderna COVID19 vaccine on 14MAY2021 and yet to receive the second dose) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant medication was not provided.  Treatment information was not provided.   Reporter did not allow further contact
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Bronchitis, Chills, Ear infection, Pyrexia, Sensory disturbance
Clinical narrative: ear infection; bronchitis; feelings of something pinching her all over; feverish; chills; This spontaneous case was reported by a consumer and describes the occurrence of EAR INFECTION (ear infection), BRONCHITIS (bronchitis), SENSORY DISTURBANCE (feelings of something pinching her all over), PYREXIA (feverish) and CHILLS (chills) in a 49-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 083821A) for COVID-19 vaccination.     Concurrent medical conditions included Allergy NOS. Concomitant products included METOPROLOL and SPIRONOLACTONE for an unknown indication.    On 22-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 22-Mar-2021, the patient experienced EAR INFECTION (ear infection), BRONCHITIS (bronchitis), SENSORY DISTURBANCE (feelings of something pinching her all over), PYREXIA (feverish) and CHILLS (chills). At the time of the report, EAR INFECTION (ear infection), BRONCHITIS (bronchitis), SENSORY DISTURBANCE (feelings of something pinching her all over), PYREXIA (feverish) and CHILLS (chills) outcome was unknown.        mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.       Patient's concomitant medication also included an unspecified allergy medication.  Treatment information was not provided.          This case was linked to MOD-2021-276536 (Patient Link).
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Intentional product use issue, Pyrexia, Sensory disturbance
Clinical narrative: Feelings of something pinching her all over, it was a nerve ending effect; Feverish; Chills; Second dose given past day 35, she received her second shot outside of the recommended time frame because she could not get time off from work; This spontaneous case was reported by a consumer and describes the occurrence of INTENTIONAL PRODUCT USE ISSUE (Second dose given past day 35, she received her second shot outside of the recommended time frame because she could not get time off from work), SENSORY DISTURBANCE (Feelings of something pinching her all over, it was a nerve ending effect), PYREXIA (Feverish) and CHILLS (Chills) in a 49-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 083821A and 083821A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included METOPROLOL and SPIRONOLACTONE for an unknown indication.   On 22-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 22-Jul-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 22-Jul-2021, the patient experienced INTENTIONAL PRODUCT USE ISSUE (Second dose given past day 35, she received her second shot outside of the recommended time frame because she could not get time off from work). On an unknown date, the patient experienced SENSORY DISTURBANCE (Feelings of something pinching her all over, it was a nerve ending effect), PYREXIA (Feverish) and CHILLS (Chills). On 22-Jul-2021, INTENTIONAL PRODUCT USE ISSUE (Second dose given past day 35, she received her second shot outside of the recommended time frame because she could not get time off from work) had resolved. At the time of the report, SENSORY DISTURBANCE (Feelings of something pinching her all over, it was a nerve ending effect), PYREXIA (Feverish) and CHILLS (Chills) outcome was unknown.            Concomitant product information also included an unspecified allergy medication.  Treatment information was not provided.   This case was linked to MOD-2021-276530 (Patient Link).
Sex: M
Vaccine: COVID19
Symptoms: Chills, Lip swelling, Pyrexia
Clinical narrative: Lip started to swell; A fever of 102 degrees Fahrenheit; Chills; This spontaneous case was reported by a consumer and describes the occurrence of LIP SWELLING (Lip started to swell), PYREXIA (A fever of 102 degrees Fahrenheit) and CHILLS (Chills) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included COVID-19 in April 2021. Previously administered products included for Product used for unknown indication: Aspirin (Patient's lip had swelled up). Past adverse reactions to the above products included Anaphylactic reaction with Aspirin.    On 02-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 03-Aug-2021, the patient experienced PYREXIA (A fever of 102 degrees Fahrenheit) and CHILLS (Chills). On 04-Aug-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced LIP SWELLING (Lip started to swell). The patient was treated with PARACETAMOL (TYLENOL) on 03-Aug-2021 for Fever and Chills, at an unspecified dose and frequency. On 03-Aug-2021, PYREXIA (A fever of 102 degrees Fahrenheit) and CHILLS (Chills) had resolved. At the time of the report, LIP SWELLING (Lip started to swell) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were provided.  The reporter stated that they have confirmed antibodies to COVID due to natural immunity.
Sex: U
Vaccine: COVID19
Symptoms: Arthralgia
Clinical narrative: joint pain; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of ARTHRALGIA (joint pain) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced ARTHRALGIA (joint pain). At the time of the report, ARTHRALGIA (joint pain) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication was reported. No treatment medication was reported.
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Herpes zoster
Clinical narrative: Shingles long after second shot; This spontaneous case was reported by a consumer and describes the occurrence of HERPES ZOSTER (Shingles long after second shot) in a 69-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 039N20A and 029L20A) for COVID-19 vaccination.     Concurrent medical conditions included Immunocompromised. Concomitant products included ACICLOVIR SODIUM (ACYCLOVIR [ACICLOVIR SODIUM]) for Antiviral treatment.   On 31-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 18-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 10-Jul-2021, the patient experienced HERPES ZOSTER (Shingles long after second shot). The patient was treated with ACRIVASTINE (BENADRYL OTC) at an unspecified dose and frequency. At the time of the report, HERPES ZOSTER (Shingles long after second shot) outcome was unknown.  For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Cardiac stress test, Nausea, Pain in jaw
Clinical narrative: jaw pain; stomach nausea; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN JAW (jaw pain) and NAUSEA (stomach nausea) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 025B214 and 030A21A) for COVID-19 vaccination.     The patient's past medical history included Lymphedema (Lymphedema of left arm) in 2002. Concurrent medical conditions included BRCA2 gene mutation (BRCA II gene positive) since 2009. Concomitant products included MULTIVITAMIN [VITAMINS NOS], CURCUMA LONGA (TURMERIC [CURCUMA LONGA]), ZINC and VITAMIN C [ASCORBIC ACID] for an unknown indication.   On 04-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 01-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced PAIN IN JAW (jaw pain) and NAUSEA (stomach nausea). At the time of the report, PAIN IN JAW (jaw pain) had not resolved and NAUSEA (stomach nausea) outcome was unknown. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Cardiac stress test: normal (normal) normal.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Other concomitant medications such as eye vitamin which patient takes daily. No treatment medications were provided by the reporter. On 01-APR-2021 patient visited doctor's office.   This case was linked to MOD-2021-041204 (Patient Link).
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Injection site pain, Pyrexia
Clinical narrative: soreness at the injection site; tiny fever; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (tiny fever) and INJECTION SITE PAIN (soreness at the injection site) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 028L20A and 039K20A) for COVID-19 vaccination.     No Medical History information was reported.   On 06-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 04-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 04-Feb-2021, the patient experienced PYREXIA (tiny fever). On 05-Feb-2021, the patient experienced INJECTION SITE PAIN (soreness at the injection site). The patient was treated with NAPROXEN SODIUM (ALEVE) for Fever and Injection site pain, at an unspecified dose and frequency. On 05-Feb-2021, PYREXIA (tiny fever) had resolved. At the time of the report, INJECTION SITE PAIN (soreness at the injection site) had resolved.            Concomitant product use was not provided by the reporter.
Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Inappropriate schedule of product administration, Miliaria, Mobility decreased, Pain, Pyrexia
Clinical narrative: Bright red, heated rash; Bright red, heated rash; Was in so much pain; Could not move; Had a fever; Patient received the 2nd dose 2 weeks after the 1st dose; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient received the 2nd dose 2 weeks after the 1st dose), RASH ERYTHEMATOUS (Bright red, heated rash), MILIARIA (Bright red, heated rash), PAIN (Was in so much pain) and MOBILITY DECREASED (Could not move) in a 57-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 01-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 15-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 15-Apr-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient received the 2nd dose 2 weeks after the 1st dose). On an unknown date, the patient experienced RASH ERYTHEMATOUS (Bright red, heated rash), MILIARIA (Bright red, heated rash), PAIN (Was in so much pain), MOBILITY DECREASED (Could not move) and PYREXIA (Had a fever). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) for Adverse event, at a dose of 2 injections. On 15-Apr-2021, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient received the 2nd dose 2 weeks after the 1st dose) had resolved. At the time of the report, RASH ERYTHEMATOUS (Bright red, heated rash), MILIARIA (Bright red, heated rash), PAIN (Was in so much pain), MOBILITY DECREASED (Could not move) and PYREXIA (Had a fever) outcome was unknown.            Concomitant medication was not provided.  Additional treatment medication included intravenous (IV) steroids.  Patient Reported that she was in Emergency Room  for 6 hours but not Hospitalised.   Most recent FOLLOW-UP information incorporated above includes: On 24-Sep-2021: Follow-Up Received contains NNI.
Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Rash erythematous
Clinical narrative: Bright red, heated rash; Bright red, heated rash; Was in so much pain; Could not move; Had a fever; Patient received the 2nd dose 2 weeks after the 1st dose; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient received the 2nd dose 2 weeks after the 1st dose), RASH ERYTHEMATOUS (Bright red, heated rash), MILIARIA (Bright red, heated rash), PAIN (Was in so much pain) and MOBILITY DECREASED (Could not move) in a 57-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 01-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 15-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 15-Apr-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient received the 2nd dose 2 weeks after the 1st dose). On an unknown date, the patient experienced RASH ERYTHEMATOUS (Bright red, heated rash), MILIARIA (Bright red, heated rash), PAIN (Was in so much pain), MOBILITY DECREASED (Could not move) and PYREXIA (Had a fever). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) for Adverse event, at a dose of 2 injections. On 15-Apr-2021, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient received the 2nd dose 2 weeks after the 1st dose) had resolved. At the time of the report, RASH ERYTHEMATOUS (Bright red, heated rash), MILIARIA (Bright red, heated rash), PAIN (Was in so much pain), MOBILITY DECREASED (Could not move) and PYREXIA (Had a fever) outcome was unknown.            Concomitant medication was not provided.  Additional treatment medication included intravenous (IV) steroids.  Patient Reported that she was in Emergency Room  for 6 hours but not Hospitalised.   Most recent FOLLOW-UP information incorporated above includes: On 24-Sep-2021: Follow-Up Received contains NNI.
Sex: M
Vaccine: COVID19
Symptoms: Fatigue, Somnolence
Clinical narrative: sleeps from 5PM to 6AM in the morning; very fatigued/Extreme tiredness; This spontaneous case was reported by a consumer and describes the occurrence of SOMNOLENCE (sleeps from 5PM to 6AM in the morning) and FATIGUE (very fatigued/Extreme tiredness) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced SOMNOLENCE (sleeps from 5PM to 6AM in the morning) and FATIGUE (very fatigued/Extreme tiredness). At the time of the report, SOMNOLENCE (sleeps from 5PM to 6AM in the morning) and FATIGUE (very fatigued/Extreme tiredness) had not resolved.            No concomitant medication information was provided. No treatment medication information was provided.   Reporter did not allow further contact
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site reaction
Clinical narrative: a spoon and tweezers stuck to her arm at the site of the injection; This spontaneous case was reported by an other health care professional and describes the occurrence of VACCINATION SITE REACTION (a spoon and tweezers stuck to her arm at the site of the injection) in a 40-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 29-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-Aug-2021, the patient experienced VACCINATION SITE REACTION (a spoon and tweezers stuck to her arm at the site of the injection). At the time of the report, VACCINATION SITE REACTION (a spoon and tweezers stuck to her arm at the site of the injection) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitants and treatment medications were reported.
Age: 72.0
Sex: F
Vaccine: COVID19
Symptoms: Incorrect route of product administration, Vaccination site erythema, Vaccination site swelling
Clinical narrative: has been told "they gave the vaccine too low in the arm it is about 5 inches down from my shoulder"; muscle at injection site has been red and swollen and is ongoing; muscle at injection site has been red and swollen and is ongoing; This spontaneous case was reported by a consumer and describes the occurrence of INCORRECT ROUTE OF PRODUCT ADMINISTRATION (has been told "they gave the vaccine too low in the arm it is about 5 inches down from my shoulder"), VACCINATION SITE SWELLING (muscle at injection site has been red and swollen and is ongoing) and VACCINATION SITE ERYTHEMA (muscle at injection site has been red and swollen and is ongoing) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 011A21A and 29K20A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included VITAMIN D [VITAMIN D NOS], METFORMIN, ATORVASTATIN CALCIUM (LIPITOR), LOSARTAN and ACETYLSALICYLIC ACID (BABY ASPIRIN) for an unknown indication.   On 04-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 04-Mar-2021, the patient experienced INCORRECT ROUTE OF PRODUCT ADMINISTRATION (has been told "they gave the vaccine too low in the arm it is about 5 inches down from my shoulder"), VACCINATION SITE SWELLING (muscle at injection site has been red and swollen and is ongoing) and VACCINATION SITE ERYTHEMA (muscle at injection site has been red and swollen and is ongoing). On 04-Mar-2021, INCORRECT ROUTE OF PRODUCT ADMINISTRATION (has been told "they gave the vaccine too low in the arm it is about 5 inches down from my shoulder") had resolved. At the time of the report, VACCINATION SITE SWELLING (muscle at injection site has been red and swollen and is ongoing) and VACCINATION SITE ERYTHEMA (muscle at injection site has been red and swollen and is ongoing) had not resolved.            No treatment medications were reported.   Most recent FOLLOW-UP information incorporated above includes: On 04-Aug-2021: Follow-up received provided no new information. On 25-Sep-2021: Follow-up received includes no new information.
Age: 67.0
Sex: F
Vaccine: COVID19
Symptoms: Nausea, Vaccination site pain
Clinical narrative: nausea; SORE ARM; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (SORE ARM) and NAUSEA (nausea) in a 67-year-old female patient who received mRNA-1273 (COVID 19 Vaccine Moderna) (batch nos. 044A21A and 030M20A) for COVID-19 vaccination.     Concurrent medical conditions included Allergic reaction to antibiotics (Reaction after Shingles vaccination.) since 2016 and Anaphylaxis since 1981.   On 11-Feb-2021, the patient received first dose of mRNA-1273 (COVID 19 Vaccine Moderna) (Intramuscular) 1 dosage form. On 13-Mar-2021, received second dose of mRNA-1273 (COVID 19 Vaccine Moderna) (unknown route) dosage was changed to 1 dosage form. On 13-Mar-2021, the patient experienced NAUSEA (nausea). On an unknown date, the patient experienced VACCINATION SITE PAIN (SORE ARM). The patient was treated with ONDANSETRON HYDROCHLORIDE (ONDANSETRAN) from 13-Mar-2021 to 15-Mar-2021 for Nauseous, at a dose of 8 mg every eight hours. On 15-Mar-2021, NAUSEA (nausea) had resolved. At the time of the report, VACCINATION SITE PAIN (SORE ARM) had resolved.            No Concomitant medications were reported. No Treatment information was reported.   This case was linked to MOD-2021-023319, MOD-2021-023319 (Patient Link).
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Blister, Herpes zoster, Oral mucosal blistering, Tongue blistering
Clinical narrative: Her doctor diagnosed it as shingles; She started with blisters on her tongue.; blisters in her mouth; She also had blisters on her chin as well on same day; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of TONGUE BLISTERING (She started with blisters on her tongue.), ORAL MUCOSAL BLISTERING (blisters in her mouth), BLISTER (She also had blisters on her chin as well on same day) and HERPES ZOSTER (Her doctor diagnosed it as shingles) in a 62-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 051C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 24-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 24-Jul-2021, the patient experienced TONGUE BLISTERING (She started with blisters on her tongue.), ORAL MUCOSAL BLISTERING (blisters in her mouth) and BLISTER (She also had blisters on her chin as well on same day). On an unknown date, the patient experienced HERPES ZOSTER (Her doctor diagnosed it as shingles). At the time of the report, TONGUE BLISTERING (She started with blisters on her tongue.), ORAL MUCOSAL BLISTERING (blisters in her mouth), BLISTER (She also had blisters on her chin as well on same day) and HERPES ZOSTER (Her doctor diagnosed it as shingles) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications provided.  No treatment medications provided.
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Intentional dose omission
Clinical narrative: Patient decided not to second dose so there is a time lapse, First dose > 35 days ago; This spontaneous case was reported by a pharmacist and describes the occurrence of INTENTIONAL DOSE OMISSION (Patient decided not to second dose so there is a time lapse, First dose > 35 days ago) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 22-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 22-Feb-2021, the patient experienced INTENTIONAL DOSE OMISSION (Patient decided not to second dose so there is a time lapse, First dose > 35 days ago). On 22-Feb-2021, INTENTIONAL DOSE OMISSION (Patient decided not to second dose so there is a time lapse, First dose > 35 days ago) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No Concomitant medication were reported No treatment information was provided.   Most recent FOLLOW-UP information incorporated above includes: On 09-Aug-2021: Follow up received with No New Information On 24-Sep-2021: follow up received contains no new information
Age: 28.0
Sex: F
Vaccine: COVID19
Symptoms: Inappropriate schedule of product administration
Clinical narrative: First dose > 35 days ago; This case was received via the regulatory authority (Reference number: 126590) on 04-Aug-2021 and was forwarded to the company on 04-Aug-2021.    This spontaneous case was reported by a pharmacist and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (First dose > 35 days ago) in a 28-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 052C21A) for COVID-19 vaccination.     No Medical History information was reported.   In January 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 02-Aug-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (First dose > 35 days ago). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (First dose > 35 days ago) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant product use was not provided. Treatment information was not provided.
Sex: U
Vaccine: COVID19
Symptoms: Arthralgia
Clinical narrative: elbow joint hurts when I move it; This spontaneous case was reported by a consumer and describes the occurrence of ARTHRALGIA (elbow joint hurts when I move it) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced ARTHRALGIA (elbow joint hurts when I move it). At the time of the report, ARTHRALGIA (elbow joint hurts when I move it) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant product use was not provided by the reporter.   Treatment information was not provided.
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Interchange of vaccine products
Clinical narrative: Caller received 1st dose of Moderna and 2nd dose Pfizer accidentally; This spontaneous case was reported by a consumer and describes the occurrence of INTERCHANGE OF VACCINE PRODUCTS (Caller received 1st dose of Moderna and 2nd dose Pfizer accidentally) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) injection for COVID-19 vaccination.    No Medical History information was reported.   On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form and TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) (unknown route) 1 dosage form. On an unknown date, the patient experienced INTERCHANGE OF VACCINE PRODUCTS (Caller received 1st dose of Moderna and 2nd dose Pfizer accidentally). At the time of the report, INTERCHANGE OF VACCINE PRODUCTS (Caller received 1st dose of Moderna and 2nd dose Pfizer accidentally) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication information was provided. No treatment medication information was provided. Patient received 1st dose of Moderna and 2nd dose Pfizer accidentally,
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia, Vaccination site erythema, Vaccination site pain, Vaccination site swelling
Clinical narrative: low grade fever; swelling; experienced some redness; pain at the injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE SWELLING (swelling), VACCINATION SITE ERYTHEMA (experienced some redness), VACCINATION SITE PAIN (pain at the injection site) and PYREXIA (low grade fever) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included COVID-19 in April 2021.    On 02-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 03-Aug-2021, the patient experienced VACCINATION SITE SWELLING (swelling), VACCINATION SITE ERYTHEMA (experienced some redness) and VACCINATION SITE PAIN (pain at the injection site). On an unknown date, the patient experienced PYREXIA (low grade fever). At the time of the report, VACCINATION SITE SWELLING (swelling), VACCINATION SITE ERYTHEMA (experienced some redness) and VACCINATION SITE PAIN (pain at the injection site) outcome was unknown and PYREXIA (low grade fever) was resolving.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No relevant concomitant medications were reported. Treatment information was unknown.  Reporter stated multiple times during the call that she and her husband have confirmed antibodies to COVID due to natural immunity.   This case was linked to MOD-2021-276552 (Patient Link).
Age: 56.0
Sex: M
Vaccine: COVID19
Symptoms: Tinnitus
Clinical narrative: everything started to echo/ He can hear himself; This spontaneous case was reported by a consumer and describes the occurrence of TINNITUS (everything started to echo/ He can hear himself) in a 56-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 034C21A) for COVID-19 vaccination.     Concurrent medical conditions included Blood pressure abnormal.    On 04-Aug-2021 at 2:30 PM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-Aug-2021 at 3:00 PM, the patient experienced TINNITUS (everything started to echo/ He can hear himself). At the time of the report, TINNITUS (everything started to echo/ He can hear himself) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications included unspecified blood pressure medication (2 types) and stomach pills (40 mg daily).  The patient reported experiencing noises like when you tap into a microphone. He reported he is a mechanic and ringing in ears is normal for him but he hasn't experienced anything like this previously.  No treatment medications were provided.   Most recent FOLLOW-UP information incorporated above includes: On 17-Aug-2021: TCR received with No New Information.
Age: 66.0
Sex: U
Vaccine: COVID19
Symptoms: Prostatic disorder
Clinical narrative: Prostate problems; This spontaneous case was reported by a consumer and describes the occurrence of PROSTATIC DISORDER (Prostate problems) in a 66-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced PROSTATIC DISORDER (Prostate problems). At the time of the report, PROSTATIC DISORDER (Prostate problems) outcome was unknown.            No concomitant medications were provided by the reporter.  Treatment information was not provided.
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: Soreness in the arm; This spontaneous case was reported by a pharmacist and describes the occurrence of VACCINATION SITE PAIN (Soreness in the arm) in a 51-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 007D21A) for COVID-19 vaccination.     No medical history was provided by the reporter.     On 22-Jun-2021 at 3:38 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE PAIN (Soreness in the arm). At the time of the report, VACCINATION SITE PAIN (Soreness in the arm) outcome was unknown.        mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications reported.  Treatment medications was not provided by the reporter   This case was linked to MOD-2021-264324 (Patient Link).
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Expired vaccine used; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 009C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 02-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Aug-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Expired vaccine used). On 02-Aug-2021, EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) had resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant information was provided by the reporter. It was reported that the vial was to expire on 30-JUL-2021 because it was removed from the freezer to store in the fridge. No treatment information was reported.
Sex: U
Vaccine: COVID19
Symptoms: Anti-thyroid antibody positive
Clinical narrative: My thyroid antibody test was also elevated; This spontaneous case was reported by a consumer and describes the occurrence of ANTI-THYROID ANTIBODY POSITIVE (My thyroid antibody test was also elevated) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   In February 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In March 2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced ANTI-THYROID ANTIBODY POSITIVE (My thyroid antibody test was also elevated). At the time of the report, ANTI-THYROID ANTIBODY POSITIVE (My thyroid antibody test was also elevated) outcome was unknown.            Lab data include thyroid antibodies were up, so patient had a thyroid antibody test done. TH3 was normal, but antibody tes. Thyroid antibody test was also elevated.  No concomitant medications were reported. Treatment information was not provided by the reporter.
Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Administered vaccination past expiration; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Administered vaccination past expiration) in a 61-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 009C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 02-Aug-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 02-Aug-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Administered vaccination past expiration). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Administered vaccination past expiration) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were mentioned. No treatment details were reported.
Sex: U
Vaccine: COVID19
Symptoms: Dizziness, Vertigo
Clinical narrative: Dizziness; Vertigo; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a physician and describes the occurrence of VERTIGO (Vertigo) and DIZZINESS (Dizziness) in an adult patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VERTIGO (Vertigo) and DIZZINESS (Dizziness). At the time of the report, VERTIGO (Vertigo) and DIZZINESS (Dizziness) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication was reported by reporter. No treatment medication was reported by reporter.   This case was linked to MOD-2021-278248, MOD-2021-278292 (Patient Link).   Reporter did not allow further contact   Most recent FOLLOW-UP information incorporated above includes: On 05-Aug-2021: event severity and outcome added for patient 1, Other relevant details added for other patients. On 06-Aug-2021: followup was received and event outcome was updated also intensity was added for both events.
Age: 80.0
Sex: F
Vaccine: COVID19
Symptoms: Inappropriate schedule of product administration
Clinical narrative: Greater than 35 days between Moderna Covid-19  vaccinations; This spontaneous case was reported by a consumer and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Greater than 35 days between Moderna Covid-19  vaccinations) in an 80-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 11-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-May-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Greater than 35 days between Moderna Covid-19  vaccinations). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Greater than 35 days between Moderna Covid-19  vaccinations) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   The patient was questioning if it is too late to receive the second dose, since the period is greater than 35 days between doses.; Sender's Comments: This report refers to a case of inappropriate schedule of product administration for mRNA-1273, batch no. 027C21A with no associated AEs.
Age: 27.0
Sex: F
Vaccine: COVID19
Symptoms: Nasal congestion, Rhinorrhoea
Clinical narrative: congestion; runny nose; This spontaneous case was reported by a consumer and describes the occurrence of NASAL CONGESTION (congestion) and RHINORRHOEA (runny nose) in a 27-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 03-Aug-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 04-Aug-2021, the patient experienced NASAL CONGESTION (congestion) and RHINORRHOEA (runny nose). At the time of the report, NASAL CONGESTION (congestion) and RHINORRHOEA (runny nose) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Additional information includes for concomitant  product where patient had reported of taking Birth control pills. Treatment information was not provided.
Sex: U
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Expired dose administered to 1 patient; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Expired dose administered to 1 patient) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 006D21A) for COVID-19 vaccination.     No medical history were reported. .     On 04-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-Aug-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Expired dose administered to 1 patient). On 04-Aug-2021, EXPIRED PRODUCT ADMINISTERED (Expired dose administered to 1 patient) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   The reporter stated that a vial was opened by a pharmacy on 03-Aug-2021. It was supposed to be discarded end of the day but it was not. The vial was left in the refrigerator and dose was administered out of puncture vial on 04-Aug-2021. No concomitants medication were provided. No treatment medication were provided.
Sex: U
Vaccine: COVID19
Symptoms: Myalgia
Clinical narrative: Soreness; This spontaneous case was reported by a consumer and describes the occurrence of MYALGIA (Soreness) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced MYALGIA (Soreness). At the time of the report, MYALGIA (Soreness) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.   No treatment information was provided.   Reporter did not allow further contact
Sex: U
Vaccine: COVID19
Symptoms: Parvovirus infection
Clinical narrative: This spontaneous case was reported by a consumer and describes the occurrence of PARVOVIRUS INFECTION (Had parvo after vaccination) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. No Medical History information was reported. On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PARVOVIRUS INFECTION (Had parvo after vaccination). At the time of the report, PARVOVIRUS INFECTION (Had parvo after vaccination) outcome was unknown. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown. No concomitant medications provided. No treatment medications provided.
Age: 36.0
Sex: M
Vaccine: COVID19
Symptoms: Cough, Exposure to SARS-CoV-2, Headache, Nasal congestion, SARS-CoV-2 test
Clinical narrative: Congestion; Vaccination site inflammation; Cough; Exposure to COVID-19; headache; This spontaneous case was reported by a consumer and describes the occurrence of NASAL CONGESTION (Congestion), VACCINATION SITE INFLAMMATION (Vaccination site inflammation ), COUGH (Cough), EXPOSURE TO SARS-COV-2 (Exposure to COVID-19) and HEADACHE (headache) in a 36-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 091D21A) for COVID-19 vaccination.     No Medical History information was reported.    On 30-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced NASAL CONGESTION (Congestion), VACCINATION SITE INFLAMMATION (Vaccination site inflammation ), COUGH (Cough), EXPOSURE TO SARS-COV-2 (Exposure to COVID-19) and HEADACHE (headache). The patient was treated with IBUPROFEN for Vaccination site inflammation, at an unspecified dose and frequency. At the time of the report, NASAL CONGESTION (Congestion), VACCINATION SITE INFLAMMATION (Vaccination site inflammation ), COUGH (Cough), EXPOSURE TO SARS-COV-2 (Exposure to COVID-19) and HEADACHE (headache) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 03-Aug-2021, SARS-CoV-2 test: negative (Negative) Negative.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were provided.  The patient stated that he  had 15 COVID tests in the last 2 years and there were no positive results. The patient also stated that these symptoms will affect his cardiovascular capacity which will affect his job.